Albert Bourla said Pfizer has discussed a fast-pass voucher with the White House during the JPMorgan Healthcare Conference.
Stocktwits on MSN
Pfizer CEO eyes big push towards obesity drug development in 2026 after $10B Metsera acquisition
Pfizer scrapped its own obesity drug candidate, Danuglipron, in early 2025, citing risks of liver enzyme elevations. ・The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback